

## Technology Appraisal Committee B Interests Register

**Topic: Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]**

**Publication Date: 15 October 2025**

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Peter Wheatley Price	TAC Committee Member	Financial	As provided for Lead Team for Talazoparib. Takeda manufacture leuprorelin which is one a number of products used to treat prostate cancer in the hormone sensitive stage. Feedback has been declare and participate.	07/07/2025	It was agreed that Peter's declaration would not prevent him from participating in discussions on this appraisal.
Rhiannon Owen	TAC Committee Member	Professional	Rhiannon has no conflicts of interest directly associated with the technologies, however, she has acted as a paid consultant participating in an Advisory Board for AstraZeneca on Dato-DXd for HR-positive HER2-negative metastatic breast cancer.	14/07/2025	It was agreed that Rhiannon's declaration would not prevent her from participating in discussions on this appraisal.
Warren Linnely	TAC Committee Member	Financial Interests	Astrazeneca is listed as a comparator company for the Talazoparib ID4004 (prostate cancer) appraisal. Warren previously provided paid consulting services to	16/07/2025	It was agreed that Warren's declaration would prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			Astrazeneca in relation to olaparib for the treatment of prostate cancer.		
David McAllister	TAC Committee Member	Financial Interests	Access trial data from some of these companies (or their competitors) for my academic research - see <a href="https://vivli.org/resources/public-disclosures/">https://vivli.org/resources/public-disclosures/</a> for details.	30/07/2025	It was agreed that David's declaration would not prevent him from participating in discussions on this appraisal.
Professor Suneil Jain	Clinical Expert	Direct Financial	Advisory boards or speaker fees or travel support in the past 3 years: Pfizer, Astra Zeneca, Bayer, Astellas, Johnston and Johnston, Boston Scientific, Teleflex, Accord, Molli surgical, BXT Nanotherapy	06/08/2025	It was agreed that Professor Jain's declaration would not prevent him from participating as an expert in this appraisal.
Holly Knight	Patient Expert	Non direct Financial	No personal interest but Prostate Cancer UK (Ms Knight's employer) stated that "Prostate Cancer UK received £300 (unrestricted small donation) from Pfizer in 2024. No other funding has been received from the manufacturer of the technology or comparator products in the last 12 months."	06/08/2025	It was agreed that Ms Knight's declaration would not prevent her from participating as an expert in this appraisal.